Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11106625 | PMC |
| http://dx.doi.org/10.6515/ACS.202405_40(3).20240129D | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous Excision of Left Atrial Myxoma Using Transcatheter Electrosurgery.
JACC Case Rep
January 2025
Cardiology Department, Centre hospitalier de l'université de Montréal, Montréal, QC, Canada.
Left atrial myxoma is the most prevalent primary cardiac tumor, known for its high risk of systemic embolization. Although surgical excision remains the standard treatment, options are limited for high-risk patients. This case report introduces a novel approach using transcatheter electrosurgery to address a left atrial myxoma via a transseptal approach in a patient ineligible for conventional surgery due to the heightened risk of intracranial hemorrhage associated with cerebral amyloid angiopathy.
View Article and Find Full Text PDFNovel Use of a Catheter-Based Device Retrieval System for Percutaneous Treatment of Recurrent Atrial Myxoma.
JACC Case Rep
January 2025
Department of Cardiology, Kaiser Permanente Downey Medical Center, Downey, California, USA.
Surgical resection is standard of care for the treatment of atrial myxoma. However, the optimal management strategy for recurrent cardiac tumors is less clear. Here we report the novel use of a catheter-based device retrieval system for the removal of a recurrent cardiac myxoma.
View Article and Find Full Text PDFTranscatheter Cardiac Tumor Excision: Growing the Toolbox.
JACC Case Rep
January 2025
St Francis Hospital and Heart Center, Roslyn, New York, USA.
Percutaneous Transcatheter Aspiration of a Large Left Atrial Mass.
JACC Case Rep
December 2024
Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
An 85-year-old woman with atrial fibrillation was found to have a large 4.5- × 3.5-cm left atrial mass.
View Article and Find Full Text PDFBackground: Heart failure (HF) patients with reduced ejection fraction (HFrEF) now more commonly die of non-cardiovascular causes than they did in the past. In patients with both HFrEF and ischemic cardiomyopathy (as the cause of HFrEF or as an accompanying condition), the effect of myocardial revascularization-i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!